EGFR and glioblastoma: This was shown in a glioblastoma model in which improved efficacy and reduced toxicity was achieved by the addition of a BiTE against EGFR, an antigen frequently overexpressed in glioblastoma but also in normal tissue, to a CAR specific for EGFRvIII, a glioblastoma-specific tumor antigen [2].